Trial Profile

Pivotal phase IIb trial of brivudine in patients with advanced pancreatic cancer.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brivudine (Primary)
Indications Pancreatic cancer
Focus Registrational; Therapeutic Use
Sponsors RESprotect

Most Recent Events

08 Feb 2016 According to a RedHill Biopharma media release, brivudine has received Orphan Drug Designation for the adjunct treatment of pancreatic cancer by the US FDA and the EMA.
30 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com